A meta‐analysis of 24 randomized‐controlled trials on diabetic patients or overweight/obese patients without diabetes demonstrated that taking GLP‐1 RAs can reduce the relative risk of major adverse cardiovascular events. The gene discussed is GLP1R; the disease is diabetes mellitus.